Extending the Time Window for Intravenous Tenecteplase in Patients With Distal Medium Vess
To assess the safety and efficacy of beyond time window TNK intravenous thrombolysis for distal Medium Vessel Occlusion (MeVO) related stroke in a prospective randomized clinical trial.
| Condition(s) | Acute Ischemic Stroke |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | To assess the safety and efficacy of beyond time window TNK intravenous thrombolysis for distal Medium Vessel Occlusion (MeVO) related stroke in a prospective randomized clinical trial. |
| Who can participate | Inclusion Criteria: 1. Evidence of a primary (e.g., not secondary to endovascular therapy of proximal vessel occlusion) distal medium vascular occlusion defined as occlusion of the co/non-dominant M2 segment\*, M3, or M4 segment of the middle cerebral artery (MCA), the anterior cerebral artery (ACA) (A1, A2, A3, or A4 segments), or the posterior cerebral artery (PCA) (P1, P2, P3, or P4 segments); \* Co/non-dominant M2 segment vessel diameter should not exceed 2.0 mm. Co-dominant supplying 50% of the MCA territory vs non-dominant supplying \<50% of the MCA territory. 2. Age ≥18 years; 3. Premorbid mRS 0-1; 4. Evidence of a disabling stroke defined as follows: 1. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥4 at the time of randomization. 2. NIHSS 2-3 with disabling def |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | The First Affiliated Hospital of University of Science and Technology of China |
| Locations | Hefei, Anhui, China |
| Start date | 2024-10-02 |
| NCT ID | NCT06559436 |
| Official listing | https://clinicaltrials.gov/study/NCT06559436 |